179 related articles for article (PubMed ID: 36504035)
1. Check this out: treatment paradigms in immune-checkpoint inhibitor colitis.
Kiparizoska S; Murphy ME; Mattar MC
Curr Opin Gastroenterol; 2023 Jan; 39(1):43-49. PubMed ID: 36504035
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E; Wallrabenstein T; König D; Cappelli LC; Naidoo J; Zippelius A; Läubli H
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233099
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors-Induced Colitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
[TBL] [Abstract][Full Text] [Related]
5. The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.
Han X; Zang D; Liu D; Chen J
Front Immunol; 2022; 13():988849. PubMed ID: 36189293
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions.
Dougan M
Immunol Rev; 2023 Sep; 318(1):11-21. PubMed ID: 37455375
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal Tract Adverse Events.
Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019
[TBL] [Abstract][Full Text] [Related]
9. Interaction between gut microbiota and immune checkpoint inhibitor-related colitis.
Zhou G; Zhang N; Meng K; Pan F
Front Immunol; 2022; 13():1001623. PubMed ID: 36389768
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer.
Chang AE; Golob JL; Schmidt TM; Peltier DC; Lao CD; Tewari M
Trends Cancer; 2021 Jul; 7(7):583-593. PubMed ID: 33741313
[TBL] [Abstract][Full Text] [Related]
11. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors.
Yanai S; Toya Y; Sugai T; Matsumoto T
Digestion; 2021; 102(6):965-973. PubMed ID: 34515105
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors.
Zhang Y; Cheng S; Zou H; Han Z; Xie T; Zhang B; Dai D; Yin X; Liang Y; Kou Y; Tan Y; Shen L; Peng Z
Front Cell Infect Microbiol; 2023; 13():1099063. PubMed ID: 37051296
[TBL] [Abstract][Full Text] [Related]
14. Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors.
Malik A; Yousaf MN; Samiullah S; Tahan V; Mahdi A
J Community Hosp Intern Med Perspect; 2023; 13(3):75-78. PubMed ID: 37877043
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.
Westdorp H; Sweep MWD; Gorris MAJ; Hoentjen F; Boers-Sonderen MJ; van der Post RS; van den Heuvel MM; Piet B; Boleij A; Bloemendal HJ; de Vries IJM
Front Immunol; 2021; 12():768957. PubMed ID: 34777387
[TBL] [Abstract][Full Text] [Related]
16. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota shed new light on the management of immune-related adverse events.
Tan B; Liu YX; Tang H; Chen D; Xu Y; Chen MJ; Li Y; Wang MZ; Qian JM
Thorac Cancer; 2022 Oct; 13(19):2681-2691. PubMed ID: 36043345
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
Gong Z; Wang Y
JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
[TBL] [Abstract][Full Text] [Related]
19. Colitis due to cancer treatment with immune check-point inhibitors - review of literature and presentation of clinical cases.
Ocepek A
Radiol Oncol; 2024 Jun; 58(2):179-185. PubMed ID: 38517981
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]